MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and VelosBio Inc. announced that the companies have entered into a definitive agreement pursuant to which MSD, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash, subject to certain customary adjustments.